Peter Bossuyt, ECCO-IBD 2022: Risankizumab in Crohn’s Disease – Post Hoc Analysis of ADVANCE, MOTIVATE, and FORTIFY
We caught up with Dr. Peter Bossuyt (Imelda General Hospital, Bonheiden, Belgium) to discuss the post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY studies which investigated risankizumab therapy by baseline Crohn’s Disease location.
The abstract ‘Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies’ (Presentation no. OP40) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- How does disease location affect treatment outcomes in Crohn’s disease? (0:13)
- Could you give us a brief overview of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies and their findings? (0:56)
- What was the rationale for the current post-hoc analysis of these study data? (2:00)
- What were the findings of the analysis? (3:14)
- How will these findings impact on the future clinical use of risankizumab in patients with Crohn’s disease? (4:58)
Disclosures: Peter Bossuyt discloses receiving financial support for research from AbbVie, Amgen, Janssen, Mundipharma, Mylan, and Pfizer; lecture fees from AbbVie, Celltrion, Janssen, Pfizer, and Takeda; and advisory board fees from AbbVie, Arena pharmaceuticals, Bristol Myers Squibb, Hospira, Janssen, Lilly, Merck, Mundipharma, Pentax Medical, Pfizer, PSI CRO, Roche, Sandoz, and Takeda.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
